Heterocyclic aza-diketone derivative as well as preparation method and application thereof
By developing heterocyclic and azadione derivatives, the problems of existing anti-monkeypox drugs to the mutant strains have been solved, effectively inhibiting monkeypox virus and reducing cytotoxicity, providing a new Potential solutions for a generation of anti-monkeypoxvirus drugs.
Patent Information
- Application Number
- CN202411355008.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-12-06
AI Technical Summary
Existing monkeypoxvirus treatment drugs such as tecovirre are tolerated to certain variants, and cidofovir and brincidofovir are less active and have side effects on monkeypoxvirus, resulting in a lack of effective new generation anti-anti-generation Monkeypox virus drug.
A heterocyclic azadione derivative and its preparation method were developed. Through anti-monkeypoxvirus activity screening, it was found that it has significant anti-monkeypoxvirus activity and low cytotoxicity, as a potential new generation anti-monkey. Poxvirus drugs.
This heterocyclic azadione derivative effectively inhibits monkeypox virus at low concentrations and has a small impact on cytotoxicity. It provides a novel anti-monkeypox virus inhibitor option with a value for further research and development.
Smart Images

Figure CN119080751A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic compound synthesis and pharmaceutical application, and specifically relates to a heterocyclic azadione derivative and a preparation method thereof and application thereof as an anti-monkeypox virus inhibitor. Background Art
[0002] Monkeypox is a zoonotic disease caused by the monkeypox virus (MPXV). MPXV belongs to the genus Orthopoxvirus along with Variolavirus (VARV), Vaccinia virus (VACV) and Cowpox virus (CPXV). The clinical manifestations of monkeypox virus are similar to those of smallpox, mainly manifested as fever, headache, muscle aches, fatigue, swollen lymph nodes and rash. The virus is mainly transmitted from animals to humans through direct contact with body fluids or lesions of infected animals, eating meat of infected animals, being scratched or bitten by animals, contact with contaminated objects, etc.; transmission between humans can be carried out through direct contact with infectious skin or other lesions in the mouth or genitals. Since the first human case of monkeypox was discovered in 1970, monkeypox has been prevalent only in some countries in central Africa. However, starting in 2022, monkeypox began to appear outside of Africa and quickly spread to more than 110 countries around the world. According to the latest statistics from the WHO, as of August 2, 2024, a total of 99,176 cases of monkeypox and 208 deaths have been reported worldwide. Among them, 2,460 cases of infection have been confirmed in China. At present, a new evolutionary branch of monkeypox (i.e., the Ib evolutionary branch) has appeared and spread rapidly in the eastern Democratic Republic of the Congo. Its four neighboring countries, Burundi, Kenya, Rwanda and Uganda, have reported more than 100 laboratory-confirmed cases of the Ib evolutionary branch, and these countries have never reported cases of monkeypox before. In addition, the Ib variant involved in this epidemic has a higher mortality rate than the previously prevalent monkeypox virus. In view of this, on August 14, 2024, the WHO once again announced that the monkeypox epidemic constituted an international public health emergency after 2022.
[0003] Small molecule antiviral drugs are still the main means of clinical treatment of viral infections. So far, only Tecovirimat has been approved by the European Medicines Agency for the treatment of monkeypox in 2020. However, mutant monkeypox virus strains resistant to Tecovirimat, such as I372N, A290V, H238Q and T289A, have recently been detected in multiple patients with HIV and monkeypox virus co-infection. In addition, the latest studies have found that Tecovirimat does not accelerate the recovery of patients infected with monkeypox type I branch strains. The nucleotide analog cidofovir and its prodrug brincidofovir can competitively inhibit the synthesis of viral DNA and have a broad spectrum of anti-orthopoxvirus activity, but they have low activity against monkeypox virus and are prone to induce mitochondrial function damage, leading to gastrointestinal and hepatotoxicity and other side effects. Therefore, medicinal chemists in various countries are still actively looking for a new generation of drugs that can effectively fight monkeypox virus.
[0004] Summary of the invention
[0005] In view of the deficiencies of the prior art, the present invention provides a heterocyclic azadione derivative and a preparation method thereof. The present invention also provides the activity screening results of the above-mentioned compounds as monkeypox virus inhibitors and their application.
[0006] The technical solution of the present invention is as follows:
[0007] 1. Heterocyclic azadione derivatives
[0008] A heterocyclic azadione derivative and its tautomer, the derivative or the deuterated derivative of the tautomer, or a pharmaceutically acceptable salt or prodrug derivative thereof of the present invention has a structure shown in the following general formula I:
[0009]
[0010] in,
[0011] n = 0, 1, 2 or 3;
[0012] X is: C or N;
[0013] Y is: -OH, -R p 、-NR p R q 、-NO2、-COOR p ;
[0014] One and only one of X and Y contains N;
[0015] V 1 N or C (U 1 );
[0016] V 2 N or C (U 2 );
[0017] V 3 N or C (U 3 );
[0018] And V 1 , V 2 and V 3 There is only one N;
[0019] Among them, U 1 , U 2 and U 3 Each is independently selected from: H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, benzyl, trifluoromethyl, -C(=O)(C1-C6 alkyl), -C(=O)NR p R q 、-NR p R q 、-NR p C(=O)R s 、-NR p C(=O)OR s 、-NR p C(=O)NR q R r 、-OR s 、-OC(=O)R s 、-OC(=O)OR s ;
[0020] R 1 is: H, -OH, C1-C6 alkyl, OC1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, -C(=O)(C1-C6 alkyl), -C(=O)NR p R q , trifluoromethyl, substituted phenyl, substituted benzyl, substituted naphthalene ring, various substituted six-membered heterocycles, various substituted five-membered heterocycles or various substituted four-membered heterocycles; the substituents are one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl;
[0021] R 2is: C1-C6 alkyl, OC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, substituted phenyl, substituted naphthalene ring, various substituted six-membered heterocycles, various substituted five-membered heterocycles, various substituted six-membered and five-membered heterocycles, various substituted six-membered and six-membered heterocycles, various substituted five-membered and five-membered heterocycles, various substituted benzo five-membered heterocycles or various substituted benzo six-membered heterocycles; the substituent is one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl;
[0022] W is: C5-C6 cycloalkyl, C4-C5 azacycloalkyl, various substituted six-membered heterocycles, various substituted five-membered heterocycles, various substituted six-membered and five-membered heterocycles, various substituted six-membered and six-membered heterocycles, various substituted five-membered and five-membered heterocycles; the substituents are one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl;
[0023] R p , R q , R s and R r is independently selected at each occurrence from hydrogen, C1-C4 alkyl and C3-C6 cycloalkyl;
[0024] in:
[0025] R p , R q , R s and R r The C1-C4 alkyl in any one of the above is optionally substituted by 1 to 3 groups selected from halogen, cyano and hydroxy;
[0026] According to the preferred embodiment of the present invention, in the general formula I,
[0027] n = 0 or 1;
[0028] X is N; Y is -OH;
[0029] R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl,
[0030] V 1 、V2 and V 3 All are C;
[0031] W is: 1,2,3-triazole, pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine;
[0032] R 2 is a substituted six-membered aromatic ring having the general formula a;
[0033]
[0034] Among them, V 4 C or N; R 3 is halogen, -OH, -OCH3, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R 3 It can be mono-, di- or tri-substituted;
[0035] In a preferred embodiment, the present invention provides a compound represented by Formula Ia and its tautomer, said derivative or deuterated derivative of said tautomer, or a pharmaceutically acceptable salt or prodrug derivative thereof,
[0036]
[0037] in,
[0038] n = 0 or 1;
[0039] R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl,
[0040] V 1 、V 2 and V 3 All are C;
[0041] R 2 is a substituted six-membered aromatic ring having the general formula a;
[0042]
[0043] Among them, V 4 C or N; R 3 is halogen, -OH, -OCH3, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R3 It can be mono-, di- or tri-substituted;
[0044] In another preferred embodiment, the present invention provides a compound represented by formula Ib and its tautomer, said derivative or deuterated derivative of said tautomer, or a pharmaceutically acceptable salt or prodrug derivative thereof,
[0045]
[0046] in,
[0047] R1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl,
[0048] V 1 、V 2 and V 3 All are C;
[0049] is: pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine;
[0050] R 2 is a substituted six-membered aromatic ring having the general formula a;
[0051]
[0052] Among them, V 4 C or N; R 3 is halogen, -OH, -OCH3, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R 3 It can be mono-, di- or tri-substituted;
[0053] According to the present invention, the heterocyclic azadione derivative represented by the general formula I is further preferably one of the following compounds:
[0055]
[0056]
[0057]
[0058] The "pharmaceutically acceptable salt" of the compound described in the present invention means that within the scope of reliable medical evaluation, the salt of the compound is suitable for contact with human or lower animal tissues without undue toxicity, irritation and allergic reaction, etc., has a fairly reasonable benefit-risk ratio, is usually water- or oil-soluble or dispersible, and can be effectively used for its intended use. It includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts, which can be used for the intended purpose and are compatible with the chemical properties of the compound of formula I. According to the present invention, a list of preferred, suitable salts is shown in SM Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19.
[0059] The "prodrugs" described in the present invention refer to pharmaceutically acceptable derivatives, so that the bioconversion products obtained from these derivatives are active drugs as defined in the compounds of formula I.
[0060] 2. A method for preparing a heterocyclic azadione derivative
[0061] The preparation method of a heterocyclic azadione derivative disclosed in the present invention can be prepared according to standard chemical practice or as described herein, including the following synthetic scheme and the representation of the compound used to prepare Formula Ia and Ib, its tautomer, the deuterated derivative of the compound or the tautomer, or the pharmaceutically acceptable salt of the foregoing.
[0062] The following non-limiting reaction schemes A and B are preferred embodiments for preparing the compounds of the present invention. Based on the reaction schemes described below and the structures of the compounds of the present invention, other methods and adjustments are obvious to those skilled in the art. These methods are all included in the scope of the present invention.
[0063] The synthesis steps of general scheme A are as follows: compound A is used as a starting material, and first reacts with N,N'-carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound B; intermediate compound B undergoes a hydrocarbonization reaction at the N-1 position under the action of potassium carbonate to form an intermediate compound C; intermediate compound C undergoes a Sonogaoka coupling reaction with trimethylsilylacetylene under the conditions of cuprous iodide, bis(triphenylphosphine)palladium dichloride as a catalyst and triethylamine as a base to obtain a key intermediate compound D; then intermediate compound D is deprotected from silicon under the action of potassium carbonate to obtain intermediate E; intermediate compound E undergoes an azide-alkynyl cycloaddition reaction under the catalysis of Cu(I) generated by the reaction of sodium ascorbate and copper sulfate pentahydrate to form an intermediate compound F; intermediate compound F is refluxed in a hydrobromic acid and glacial acetic acid system to deprotect the benzyl group to generate the target product Ia.
[0064] The synthetic route is as follows:
[0065]
[0066] Reagents and conditions: (i) (a) N, N'-carbonyldiimidazole, tetrahydrofuran; (b) o-benzylhydroxylamine, reflux; (c) sodium hydroxide, ethanol, reflux; (d) acetic acid, room temperature; (ii) iodinated alkanes, iodinated cycloalkanes, iodinated olefins, iodinated alkynes, iodinated heteroatom-containing alkanes or iodinated heteroatom-containing cycloalkanes, K2CO3, N, N-dimethylformamide, room temperature or bromoalkanes, bromocycloalkanes, bromoolefins, bromoalkynes, Brominated heteroatom-containing alkane or brominated heteroatom-containing cycloalkane, K2CO3, KI, N,N-dimethylformamide, 20-65°C; (iii) cuprous iodide, bis(triphenylphosphine)palladium dichloride, triethylamine, trimethylsilylacetylene, tetrahydrofuran, room temperature; (iv) potassium carbonate, methanol, room temperature; (v) sodium ascorbate, copper sulfate pentahydrate, water, tetrahydrofuran, azide, 20-65°C; (vi) hydrobromic acid, acetic acid, reflux.
[0067] R 1 , R 2 、V 1 , V 2 , V 3 and n are the same as those shown in the above general formula Ia.
[0068] The azide is a substituted benzene ring azide, a substituted naphthalene ring azide, various substituted six-membered heterocyclic azides, various substituted five-membered heterocyclic azides, various substituted six-membered and five-membered heterocyclic azides, various substituted six-membered and six-membered heterocyclic azides, and various substituted five-membered and five-membered heterocyclic azides; the substituent is one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl.
[0069] The synthesis steps of general scheme B are as follows: the intermediate compound C obtained in general scheme A is used as a starting material, and various boronic acid-substituted nitrogen-containing heterocycles whose amino groups are protected by Boc are subjected to Suzuki reaction under the conditions of tetrakistriphenylphosphine palladium as a catalyst and sodium carbonate as a base to obtain intermediate compound G; intermediate compound G is deprotected from the amino group under acidic or alkaline conditions to obtain intermediate compound H; intermediate compound H is subjected to nucleophilic substitution with a halogen-substituted benzyl group under alkaline conditions to obtain intermediate compound J; intermediate compound J is refluxed in a hydrobromic acid and glacial acetic acid system to deprotect the benzyl group to generate the target product Ib.
[0070]
[0071] Reagents and conditions: (i) various amino groups substituted with boric acid protected by Boc, nitrogen-containing heterocycles, sodium carbonate, tetrakis(triphenylphosphine)palladium, 1,4-dioxane / water, microwave at 120℃-130℃; (ii) hydrochloric acid in ethyl acetate, room temperature or potassium carbonate, methanol, reflux (iii) potassium carbonate or sodium hydrogen sulfide, N,N-dimethylformamide, room temperature; (iv) hydrobromic acid, acetic acid, reflux.
[0072] R 1 , R 2 、V 1 , V 2 and V 3 Same as the above general formula Ib.
[0073] The nitrogen-containing heterocyclic ring in which the various amino groups are replaced by boric acid protected by Boc is pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine.
[0074] The halogen-substituted benzyl aromatic ring is the same as the substituted six-membered aromatic ring having the general formula a shown in the above general formula I.
[0075] According to a preferred embodiment of the present invention, a method for preparing a heterocyclic azadione derivative comprises the following specific steps:
[0076] Synthetic steps of general method A:
[0077] (1) Add the starting material compound A to anhydrous tetrahydrofuran, then add N,N'-carbonyldiimidazole to the solution, stir for 1-3 hours at room temperature; then add o-benzylhydroxylamine, heat and reflux for 1-3 hours; evaporate the solvent, then add ethanol to the residue to dissolve, add sodium hydroxide and continue to reflux for 1-3 hours; cool to room temperature, add glacial acetic acid to acidify to produce a large amount of white precipitate; filter, and wash the precipitate with ice water to obtain the intermediate compound B;
[0078] (2) Dissolve the intermediate compound B in N,N-dimethylformamide, add potassium carbonate and iodinated alkanes, iodinated cycloalkanes, iodinated olefins, iodinated alkynes, iodinated heteroatom-containing alkanes or iodinated heteroatom-containing cycloalkanes, and stir at 20-65° C. for 1-3 h; add a large amount of water to the reaction solution to quench the reaction, produce a large amount of white precipitate, filter, and wash with water to obtain a crude product of the intermediate compound C;
[0079] (3) To an anhydrous tetrahydrofuran solution containing the intermediate compound C, bis(triphenylphosphine)palladium dichloride, cuprous iodide and triethylamine are added in sequence, and trimethylsilyl acetylene is added to the mixed solution under nitrogen protection, and stirred at room temperature for 8-12 hours; the reaction solution is filtered through diatomaceous earth, and the filtrate is concentrated to obtain a crude product of the intermediate compound D; the obtained intermediate compound D is dissolved in a methanol solution, potassium carbonate is added, and stirred at room temperature for 1-3 hours; a saturated sodium bicarbonate aqueous solution is added to the reaction solution to generate a large amount of precipitate, which is filtered and washed with water to obtain a crude product of the key intermediate compound E;
[0080] (4) Dissolving the key intermediate compound E and azide in a tetrahydrofuran solution, and then adding an aqueous solution of sodium ascorbate and copper sulfate pentahydrate to the solution; stirring at 20-65° C. for 4-12 hours; after the reaction is completed, adding an appropriate amount of water to the reaction solution to generate a large amount of precipitate, filtering, washing the filter cake with water, and drying the filter cake to obtain a crude product of the intermediate compound F of the target product;
[0081] (5) Add glacial acetic acid and hydrobromic acid to the intermediate compound F prepared in the previous step, heat under reflux for 0.5-2 h, cool to room temperature, concentrate under reduced pressure, and then recrystallize from methanol to obtain the target product Ia.
[0082] Synthetic steps of general method B:
[0083] (1) Adding intermediate compound C, various amino groups substituted by boric acid protected by Boc to nitrogen-containing heterocyclic rings, tetrakis(triphenylphosphine)palladium to a 1,4-dioxane solution, and then adding an aqueous solution of sodium carbonate, and microwave reaction at 120°C-130°C for 20-30 minutes; then filtering the reaction solution with diatomaceous earth, and evaporating the filtrate to obtain a crude intermediate compound G;
[0084] (2) Add 2M hydrochloric acid ethyl acetate solution to the intermediate compound G, stir and react at room temperature for 0.5-3h; after the reaction is complete, evaporate the solvent under reduced pressure, add saturated sodium bicarbonate aqueous solution to the concentrate, stir at room temperature for 0.5h, filter, wash the filter cake with water, and dry the filter cake to obtain a crude intermediate compound H of the target product; or dissolve the intermediate compound G in methanol solution, add potassium carbonate, and reflux for 0.5-2h; evaporate the solvent under reduced pressure, add aqueous solution to the concentrate, stir at room temperature for 0.5h, filter, and dry the filter cake to obtain a crude intermediate compound H of the target product;
[0085] (3) dissolving the obtained intermediate compound H in N,N-dimethylformamide solution, adding potassium carbonate, potassium iodide or sodium hydrogen hydride, and stirring at room temperature for 2-12 hours; slowly adding water dropwise to the reaction solution to generate a large amount of precipitate, filtering, washing the filter cake with water, and drying the filter cake to obtain a crude product of the intermediate compound J;
[0086] (4) Add glacial acetic acid and hydrobromic acid to the intermediate compound J prepared in the previous step, heat under reflux for 0.5-2 h, cool to room temperature, concentrate under reduced pressure, and then recrystallize from methanol to obtain the target product Ib.
[0087] The room temperature described in the present invention refers to 20-30°C.
[0088] 3. Application of a heterocyclic azadione derivative
[0089] Anti-monkeypox virus activity and toxicity experiments of target compounds
[0090] The present invention screened the anti-monkeypox virus activity of some heterocyclic azadione derivatives synthesized according to the above method, and their antiviral activity and toxicity data are listed in Table 1, with Cidofovir, Brincidofovir and Tecovirimat as positive controls.
[0091] It can be seen from Table 1 that most of the newly synthesized heterocyclic azepine dione derivatives exhibit significant anti-monkeypox virus activity. Among them, the anti-monkeypox virus activities of compounds Ia-7-3, Ia-7-10, Ia-7-11, Ia-7-20, Ia-7-21, Ia-7-24, Ia-7-25, Ia-7-26, Ia-7-27, Ia-7-28 and Ia-7-29 are all less than 100 nM. In addition, most of the newly synthesized heterocyclic azepine dione derivatives do not show obvious cytotoxicity and have further research and development value.
[0092] The heterocyclic azadione derivatives of the invention are a series of anti-monkeypox virus inhibitors with novel structures and can be used as anti-monkeypox virus lead compounds.
[0093] The heterocyclic azadione derivative of the present invention can be used as a monkeypox virus inhibitor, and specifically, can be used as an anti-monkeypox virus inhibitor for preparing anti-monkeypox virus drugs.
[0094] An anti-monkeypox virus pharmaceutical composition comprises a heterocyclic azapine dione derivative of the present invention and one or more pharmaceutically acceptable carriers or excipients.
[0095] The present invention discloses the results of anti-monkeypox virus activity screening of a heterocyclic azepine dione derivative and its first application as a monkeypox virus inhibitor. Experiments prove that the heterocyclic azepine dione derivative of the present invention can be used as a monkeypox virus inhibitor for preparing anti-monkeypox virus drugs.
[0096] The present invention provides a novel heterocyclic azepine dione derivative and a preparation method thereof, and also provides the first application of the compound in a monkeypox virus inhibitor. Experiments have shown that the heterocyclic azepine dione derivative of the present invention can be used as a monkeypox virus inhibitor and has a high application value. Specifically, the monkeypox virus inhibitor is used to prepare an anti-monkeypox drug. DETAILED DESCRIPTION
[0097] The following examples are provided to help understand the present invention, but they cannot limit the content of the present invention.
[0098] Example 1: Preparation of 3-(Benzyloxy)-6-iodoquinazoline-2,4(1H,3H)-dione (Ia-1)
[0099]
[0100] Add methyl 2-amino-5-iodobenzoate (13.7mmol, 4.0g) to 75mL of anhydrous tetrahydrofuran, then add N,N'-carbonyldiimidazole (20.6mmol, 3.3g) to the solution and stir for 2h at room temperature. Then add o-benzylhydroxylamine (20.6mmol, 2.54g) and heat to reflux for 2h. Evaporate the solvent, add 120mL of ethanol to the residue to dissolve, add sodium hydroxide (20.6mmol, 0.8g), and continue to reflux for 2h. Cool to room temperature, add glacial acetic acid to acidify to produce a large amount of white precipitate. Filter and wash the precipitate with ice water. Recrystallize from methanol to obtain the product 3-(benzyloxy)-6-iodoquinazoline-2,4(1H,3H)-dione (Ia-1), a white solid with a yield of 62.7%, mp: 262-264℃. 1 HNMR(400MHz,DMSO-d6)δ11.75(1H,s),8.18(1H,d,J=1.88Hz),7.97(1H,dd,J=8.52,1.92H z),7.57(2H,dd,J=7.68,1.92Hz),7.40-7.44(3H,m),7.02(1H,d,J=8.56Hz),5.10(2H,s).
[0101] Example 2: Preparation of intermediate compounds Ia-2a-Ia-2h
[0102]
[0103] 3-(Benzyloxy)-6-iodoquinazoline-2,4(1H,3H)-dione (Ia-1) (5.1mmol, 2.0g) was added to 20mL of N,N-dimethylformamide, and then potassium carbonate (10.2mmol, 1.4g) and iodoalkane or iodocycloalkane (10.2mmol) were added to the solution, and stirring was continued at room temperature for 1-3h. A large amount of water was added to the reaction solution to quench the reaction, and a large amount of white precipitate was produced; filtered and washed with water to obtain the crude intermediate compound Ia-2a-Ia-2h, which was recrystallized from methanol to obtain the pure intermediate compound Ia-2a-Ia-2h.
[0104]
[0105] The preparation of the intermediate compound 3-(benzyloxy)-6-iodo-1-methylquinoline-2,4(1H,3H)-dione (Ia-2a) was carried out in the same manner as above, except that iodomethane was used. White solid, yield 98%, mp: 195-197°C. ESI-MS: m / z 431.45 (M+Na) + ,838.89(2M+Na) + .C 16 H 13 IN2O3(408.00). 1 H NMR(400MHz,DMSO-d6)δ8.27(1H,d,J=2.08Hz),8.08(1H,dd,J=8.80,2.12Hz),7.58(2H,d d,J=7.68,2.24Hz),7.40-7.44(3H,m),7.28(1H,d,J=8.84Hz),5.08(2H,s),3.51(3H,s).
[0106]
[0107] The preparation of the intermediate compound 3-(benzyloxy)-1-ethyl-6-iodoquinoline-2,4(1H,3H)-dione (Ia-2b) was carried out in the same manner as above, except that iodoethane was used. White solid, yield 96%, mp: 136-138°C. ESI-MS: m / z 445.59 (M+Na) + ,866.98(2M+Na) + .C 17 H 15 IN2O3(422.01). 1H NMR (400MHz, DMSO-d6) δ8.29 (1H, d, J = 2.12Hz), 8.07 (1H, dd, J = 8.84, 2.16Hz), 7.58 (2H, dd, J = 7.68,2.36Hz),7.35-7.44(4H,m),5.10(2H,s),4.15(2H,q,J=6.96Hz),1.22(3H,t,J=7.08Hz).
[0108]
[0109] The preparation of the intermediate compound 3-(benzyloxy)-6-iodo-1-propylquinoline-2,4(1H,3H)-dione (Ia-2c) was carried out in the same manner as above, except that 1-iodopropane was used. White solid, yield 89%, mp: 128-130°C. ESI-MS: m / z 437.59 (M+H) + ,895.02(2M+Na) + .C 18 H 17 IN2O3(436.03). 1 H NMR(400MHz,DMSO-d6)δ8.29(d,J=2.2Hz,1H),8.05(dd,J=8.9,2.2Hz,1H),7.61–7.52(m,2H),7 .46–7.34(m,4H),5.10(s,2H),4.04(t,J=7.6Hz,2H),1.70–1.56(m,2H),0.94(t,J=7.4Hz,3H).
[0110]
[0111] The preparation of the intermediate compound 1-allyl-3-(benzyloxy)-6-iodoquinoline-2,4(1H,3H)-dione (Ia-2d) was carried out in the same manner as above, except that 3-iodopropene was used. White solid, yield 85%, mp: 160-162°C. ESI-MS: m / z 457.55 (M+Na) + ,891.00(2M+H) + .C 18 H 15 IN2O3(434.01). 1H NMR(400MHz, DMSO-d6)δ8.30(d,J=2.2Hz,1H),8.04(dd,J=8.8,2.2Hz,1H),7.61–7.52(m,2H),7.46–7.36(m ,3H),7.19(d,J=8.9Hz,1H),5.99–5.84(m,1H),5.21–5.13(m,2H),5.12(s,2H),4.74(dt,J=4.3,1.9Hz,2H).
[0112]
[0113] The preparation of the intermediate compound 3-(benzyloxy)-6-iodo-1-isobutylquinoline-2,4(1H,3H)-dione (Ia-2e) was carried out in the same manner as above, except that isobutyl iodide was used. White solid, yield 90%, mp: 108-110°C. ESI-MS: m / z 451.11 (M+H) + ,923.11(2M+Na) + .C 19 H 19 IN2O3(450.04). 1 H NMR(400MHz, DMSO-d6)δ8.30(d,J=2.2Hz,1H),8.04(dd,J=8.9,2.2Hz,1H),7.59–7.52(m,2H),7.45–7.37( m,3H),7.35(d,J=9.0Hz,1H),5.10(s,2H),3.95(d,J=7.6Hz,2H),2.13–2.00(m,1H),0.91(d,J=6.7Hz,6H).
[0114]
[0115] The preparation of the intermediate compound 3-(benzyloxy)-6-iodo-1-(2-methylbutyl)quinoline-2,4(1H,3H)-dione (Ia-2f) was carried out in the same manner as above, except that 1-iodo-2-methylbutane was used. White solid, yield 86%, mp: 104-106°C. ESI-MS: m / z 465.84 (M+H) + ,951.08(2M+Na) + .C 20 H 21 IN2O3(464.06). 1H NMR(400MHz, DMSO-d6)δ8.30(d,J=2.2Hz,1H),8.05(dd,J=8.8,2.2Hz,1H),7.59–7.52(m,2H),7.46–7.36(m,3H),7.32(d, J=9.0Hz,1H),5.10(s,2H),4.03–3.90(m,2H),1.93–1.78(m,1H),1.48–1.36(m,1H),1.24–1.09(m,1H),0.91–0.82(m,6H).
[0116]
[0117] The preparation of the intermediate compound 3-(benzyloxy)-6-iodo-1-isopentylquinoline-2,4(1H,3H)-dione (Ia-2g) was carried out in the same manner as above, except that iodoisopentane was used. White solid, yield 87%, mp: 102-104°C. ESI-MS: m / z 465.37 (M+H) + ,951.12(2M+Na) + .C 20 H 21 IN2O3(464.06). 1 H NMR(400MHz, DMSO-d6)δ8.30(d,J=2.2Hz,1H),8.07(dd,J=8.8,2.2Hz,1H),7.60–7.53(m,2H),7.46–7.36(m,3H),7. 29(d,J=8.9Hz,1H),5.10(s,2H),4.09(t,J=7.9Hz,2H),1.75–1.60(m,1H),1.54–1.42(m,2H),0.96(d,J=6.6Hz,6H).
[0118]
[0119] The preparation of the intermediate compound 3-(benzyloxy)-1-(cyclobutylmethyl)-6-iodoquinoline-2,4(1H,3H)-dione (Ia-2h) was carried out in the same manner as above, except that (iodomethyl)cyclobutane was used. White solid, yield 91%, mp: 116-118°C. ESI-MS: m / z 463.50 (M+H) + ,947.09(2M+Na) + .C 20 H 19 IN2O3(462.04). 1H NMR(400MHz, DMSO-d6)δ8.28(d,J=2.2Hz,1H),8.04(dd,J=8.8,2.2Hz,1H),7.59–7.52(m,2H),7.46–7.38 (m,3H),7.35(d,J=8.9Hz,1H),5.10(s,2H),4.17(d,J=7.1Hz,2H),2.75–2.62(m,1H),2.02–1.72(m,6H).
[0120] Example 3: Preparation of Azides (Ia-3a-Ia-3m)
[0121]
[0122] Polysubstituted benzyl bromide (1.0 equiv) was added to N,N-dimethylformamide, and then sodium azide (1.2 equiv) was added to the solution, and stirred at room temperature for 24 hours. Saturated sodium chloride solution was added to the reaction solution, and then extracted with tetrahydrofuran solution; the organic phase obtained by extraction was washed with saturated sodium chloride solution to obtain tetrahydrofuran solution of azide (Ia-3a-Ia-3m).
[0123] Example 4: Preparation of target compounds (Ia-7-1-Ia-7-29)
[0124]
[0125] To a 20 mL anhydrous tetrahydrofuran solution containing intermediate compound Ia-2a-Ia-2h (1.0 equiv), bis(triphenylphosphine)palladium dichloride (0.05 equiv), cuprous iodide (0.2 equiv) and triethylamine (4.0 equiv) were added in sequence, and then nitrogen was added for protection. Then trimethylsilyl acetylene (2.2 equiv) was added to the mixed solution, and stirred at room temperature for 24 h. The reaction solution was filtered through a diatomaceous earth pad, and the filtrate was concentrated to obtain a crude intermediate compound Ia-4a-Ia-4h; the crude intermediate compound Ia-4a-Ia-4h was dissolved in a methanol solution, potassium carbonate (1.1 equiv) was added, and stirred at room temperature for 1-3 h; a saturated sodium bicarbonate aqueous solution was added to the reaction solution to produce a large amount of precipitate, which was filtered and washed with water to obtain a crude key intermediate compound Ia-5a-Ia-5h; the key intermediate compound Ia-5a-Ia-5h (1.0 equiv) was added to a tetrahydrofuran solution of azide (Ia-3a-Ia-3m), and then Add an aqueous solution of sodium ascorbate (0.1 equiv) and copper sulfate pentahydrate (0.5 equiv) to this solution; stir at 20-65°C for 4-12 h; after the reaction is completed, add an appropriate amount of water to the reaction solution to generate a large amount of precipitate, filter, wash the filter cake with water, and dry the filter cake to obtain the crude product of the target product Ia-6a-Ia-6h; add 3 mL of glacial acetic acid and 2 mL of hydrobromic acid to the intermediate compound Ia-6-1-Ia-6-29 (0.4 mmol), heat to reflux for 0.5-2 h; cool to room temperature, concentrate under reduced pressure; then recrystallize from methanol to obtain the target product Ia-7-1-Ia-7-29.
[0126]
[0127] The preparation of the target compound 3-hydroxy-1-methyl-6-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-1) was carried out in the same manner as above. White solid, yield 72%, mp: 218-220°C. ESI-MS: m / z 418.27 (M+H) + ,834.74(2M+H) + .C 19 H 14 F3N5O3(417.10). 1H NMR (400MHz, DMSO-d6) δ10.83(s,1H),8.87(s,1H),8.50(d,J=2.1Hz,1H),8.24(dd,J=8 .8,2.1Hz,1H),7.79(d,J=8.0Hz,2H),7.57(t,J=7.6Hz,3H),5.80(s,2H),3.56(s,3H). 13 C NMR(100MHz,DMSO-d6)δ158.87,149.66,145.87,140.97,139.40,132.04,129.22,129.21( 2 J CF =31.8Hz,3C),126.27,126.23,126.19,126.16,125.85,124.57( 1 J CF =272.2Hz,27C),124.04,122.58,116.12,115.80,52.95,31.35.
[0128]
[0129] The preparation of the target compound 3-hydroxy-1-methyl-6-(1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-2) was carried out in the same manner as above. White solid, yield 72%, mp: 228-230°C. ESI-MS: m / z 418.27 (M+H) + .C 19 H 14 F3N5O3(417.10). 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.88(d,J=1.1Hz,1H),8.50(s,1H),8.24(dd,J=8.8,2.3Hz,1H), 7.81(s,1H),7.74(d,J=7.0Hz,1H),7.70–7.62(m,2H),7.56(d,J=8.7Hz,1H),5.79(s,2H),3.56(s,3H). 13 C NMR (100MHz, DMSO-d6) δ158.87,149.66,145.84,139.41,137.68,132.75,132.06,130.51,129.91( 2 J CF =31.8Hz,5C),125.85,125.57,125.52(3 J CF =3.7Hz,4C),125.31,125.26( 3 J CF =3.7Hz, 6C),124.04,123.14,122.50,116.13,115.81,52.89,31.35.
[0130]
[0131] The preparation of the target compound 6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxy-1-methylquinoline-2,4(1H,3H)-dione (Ia-7-3) was carried out in the same manner as above. White solid, yield 75%, mp: 222-224°C. ESI-MS: m / z 436.31 (M+H) + ,870.73(2M+H) + ,C 19 H 13 F4N5O3(435.10). 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.87(s,1H),8.50(d,J=2.1Hz,1H),8.25(dd,J=8.7 ,2.2Hz,1H),7.84(t,J=7.9Hz,1H),7.61–7.53(m,2H),7.37(d,J=8.1Hz,1H),3.57(s,3H). 13 C NMR(100MHz,DMSO-d6)δ159.34( 1 J CF =253.0Hz,5C),158.08,149.66,145.90,144.18,144.10,139.43,132.05,128.47,128.43,125.80,125.01,124.98,124.34,124.08,122.99( 1 J CF =272.2Hz,28C),117.31,117.10,116.75(J CF =32.3,12.0Hz,4C),116.13,115.80,52.44,31.36.
[0132]
[0133] The preparation of the target compound 6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxy-1-methylquinoline-2,4(1H,3H)-dione (Ia-7-4) was carried out in the same manner as above. White solid, yield 75%, mp: 228-230°C. ESI-MS: m / z 436.31 (M+H) + ,870.74(2M+H) + .C 19 H 13 F4N5O3(435.10). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.86(s,1H),8.50(d,J=2.1Hz,1H),8.25(dd,J=8.8,2.2Hz,1 H),7.80(dd,J=9.9,1.5Hz,1H),7.70–7.59(m,2H),7.57(d,J=8.8Hz,1H),5.83(s,2H),3.56(s,3H). 13 C NMR(100MHz,DMSO-d6)δ160.36( 1 J CF =249.8Hz,2C),158.88,149.66,145.76,139.42,132.45,132.41,132.08,127.92( 3 J CF =14.9Hz, 6C),125.77,124.99,124.05,122.65,122.39,122.35,122.31,116.15,115.79,113.88,113.64,47.34,31.36.
[0134]
[0135] The preparation of the target compound 3-hydroxy-6-(1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl)-1-methylquinoline-2,4(1H,3H)-dione (Ia-7-5) was carried out in the same manner as above. Yellow solid, yield 55%, mp: 194-196°C. ESI-MS: m / z 380.16 (M+H) + ,758.81(2M+H) + .C 19 H 17 N5O4(379.13). 1H NMR(400MHz,DMSO-d6)δ10.81(s,1H),8.83(s,1H),8.50(s,1H),8.25(s,1H),7.57(s,1H),7.31 (t,J=7.8Hz,1H),7.01–6.87(m,2H),6.83–6.65(m,1H),5.61(s,2H),3.75(s,3H),3.56(s,3H). 13 C NMR(100MHz,DMSO-d6)δ158.88,158.13,149.66,145.73,139.34,137.69,132.04,130 .33,125.99,123.97,122.33,118.86,116.09,115.80,115.61,115.05,53.57,31.34.
[0136]
[0137] The preparation of the target compound 3-hydroxy-6-(1-(3-hydroxybenzyl)-1H-1,2,3-triazol-4-yl)-1-methylquinoline-2,4(1H,3H)-dione (Ia-7-6) was carried out in the same manner as above. White solid, yield 65%, mp: 278-282°C. ESI-MS: m / z 366.19 (M+H) + ,730.88(2M+H) + .C 18 H 15 N5O4(365.11). 1 H NMR (400MHz, DMSO-d6) δ10.76(s,1H),9.49(s,1H),8.75(s,1H),8.43(d,J=2.2Hz,1H),8.17(dd,J=8.8,2.2Hz,1H),7.50 (t,J=8.9Hz,1H),7.12(td,J=7.5,1.3Hz,1H),6.72(dt,J=7.7,1.4Hz,1H),6.70–6.57(m,2H),5.49(s,2H),3.49(s,3H). 13 C NMR(100MHz,DMSO-d6)δ158.88,158.13,149.66,145.73,145.63,139.34,137.69,132.04,130.33 ,129.95,128.86,125.99,123.97,122.33,118.86,116.09,115.80,115.61,115.05,53.57,31.34.
[0138]
[0139] The preparation of the target compound 3-hydroxy-1-methyl-6-(1-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-7) was carried out in the same manner as above. White solid, yield 63%, mp: 234-236°C. ESI-MS: m / z 419.30 (M+H) + ,836.67(2M+H) + .C 18 H 13 F3N6O3(418.10). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.99–8.79(m,2H),8.49(d,J=2.1Hz,1H),8.24(dd,J=8.7,2.1Hz, 1H),8.06(dd,J=8.5,2.1Hz,1H),7.97(d,J=8.1Hz,1H),7.57(d,J=8.8Hz,1H),5.87(s,2H),3.56(s,3H). 13 C NMR(100MHz,DMSO-d6)δ158.87,150.41,149.66,146.66(J CF =219.7,44.3Hz,3C),145.93,139.42,138.65,135.87,132.02,125.76,124.06,123.36,122.00( 1 J CF =274.0Hz,27C),121.49,121.47,121.44,116.14,115.79,50.57,31.35.
[0140]
[0141] The preparation of the target compound 1-ethyl-3-hydroxy-6-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-8) was carried out in the same manner as above. White solid, yield 64%, mp: 244-248°C. ESI-MS: m / z 432.28 (M+H) + ,862.73(2M+H) + .C 20 H 16 F3N5O3(431.12). 1H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.87(s,1H),8.51(d,J=2.1Hz,1H),8.23(dd,J=8.7,2.2Hz,1H),7.78(d,J=8 .1Hz,2H),7.63(d,J=8.9Hz,1H),7.58(d,J=8.0Hz,2H),5.80(s,2H),4.19(q,J=7.0Hz,2H),1.24(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ158.78,149.20,145.86,140.96,138.30,132.22,126.23( 2 J CF =3.6Hz,4C,6C),125.82,124.57( 1 J CF =272.2Hz,28C),124.40,122.57,116.07,115.85,52.96,12.98.
[0142]
[0143] The preparation of the target compound 1-ethyl-3-hydroxy-6-(1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-9) was carried out in the same manner as above. White solid, yield 62%, mp: 234-236°C. ESI-MS: m / z 432.26 (M+H) + .C 20 H 16 F3N5O3(431.12). 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.89(d,J=2.2Hz,1H),8.51(t,J=2.2Hz,1H),8.24(dt,J=8.7,2.2Hz,1H),7.81 (s,1H),7.74(t,J=4.2Hz,1H),7.70–7.59(m,3H),5.79(d,J=2.2Hz,2H),4.19(q,J=7.4Hz,2H),1.24(t,J=6.1Hz,3H). 13 C NMR (125MHz, DMSO-d6) δ158.78,149.20,145.83,138.29,137.70,132.72,132.21,130.49,129.93( 2 J CF=31.8Hz,5C),127.74,125.81,125.57,125.54,125.49( 3 J CF =3.9Hz,4C),125.22( 3 J CF =3.8Hz, 6C),124.39,123.41,122.49,116.07,115.85,52.90,39.09,12.97.
[0144]
[0145] The preparation of the target compound 1-ethyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-10) was carried out in the same manner as above. White solid, yield 68%, mp: 236-238°C. ESI-MS: m / z 450.33 (M+H) + ,898.74(2M+H) + ,C 20 H 15 F4N5O3(449.11). 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.87(s,1H),8.52(d,J=2.1Hz,1H),8.24(dd,J=8.8,2.2Hz,1H),7.84(t,J =7.9Hz,1H),7.67–7.53(m,2H),7.37(d,J=8.1Hz,1H),5.81(s,2H),4.19(q,J=7.0Hz,2H),1.25(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ159.33( 1 J CF =252.0Hz,7C),158.81,149.20,145.87,144.20,144.12,138.31,132.20, 128.48,128.43,125.73,124.99,124.96,124.39,124.33,122.73,120.28( 1 J CF =270.1Hz,29C),117.29,117.08,116.74(J CF =32.2,12.2Hz,6C),116.05,115.89,52.43,13.00.
[0146]
[0147] The preparation of the target compound 1-ethyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-11) was carried out in the same manner as above. White solid, yield 72%, mp: 236-238°C. ESI-MS: m / z 450.23 (M+H) + .C 20 H 15 F4N5O3(449.11). 1 H NMR (400MHz, DMSO-d6) δ10.72(s,1H),8.85(s,1H),8.51(d,J=2.1Hz,1H),8.24(dd,J=8.7,2.2Hz,1H) ,7.79(d,J=10.0Hz,1H),7.72–7.56(m,3H),5.83(s,2H),4.19(q,J=7.0Hz,2H),1.24(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ160.36( 1 J F =249.7Hz,4C),158.80,149.20,145.75,138.31,132.42,132.39,132.23,131.50(J CF =32.9,8.3Hz,6C),127.92( 2 J CF =14.8Hz,7C),125.73,124.41,122.66,116.06,115.87,113.78( 2 J F =24.9Hz,5C),47.31,13.00.
[0148]
[0149] The preparation of the target compound 1-ethyl-6-(1-(2-fluoro-5-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-12) was carried out in the same manner as above. Yellow solid, yield 68%, mp: 210-212°C. ESI-MS: m / z 450.21 (M+H) + .C 20 H 15 F4N5O3(449.11). 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.86(s,1H),8.51(d,J=2.1Hz,1H),8.24(dd,J=8.7,2.2Hz,1H),7.95(d,J=6.3Hz,1H),7.8 8(dd,J=8.2,4.4Hz,1H),7.62(d,J=8.9Hz,1H),7.55(t,J=9.1Hz,1H),5.81(s,2H),4.19(q,J=7.0Hz,2H),1.24(t,J=7.0Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ162.98( 1 J CF =254.3Hz,2C),158.78,149.20,145.67,138.31,132.24,129.16,129.13,129. 09,129.03,128.95,126.26,126.02,125.74,124.52,124.42,124.39,124.13( 1 J CF =272.1Hz,29C),122.50,117.59( 2 J CF =22.7Hz,1C),116.06,115.84,47.37,39.08,12.97.
[0150]
[0151] The preparation of the target compound 1-ethyl-6-(1-(2-fluoro-3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-13) was carried out in the same manner as above. Yellow solid, yield 59%, mp: 250-252°C. ESI-MS: m / z 450.22 (M+H) + .C 20 H 15 F4N5O3(449.11). 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.87(d,J=1.5Hz,1H),8.51(t,J=1.7Hz,1H),8.24(dd,J=8.7,2.4Hz,1H),7.83(t,J=7.5Hz, 1H),7.75(t,J=7.4Hz,1H),7.63(d,J=8.8Hz,1H),7.47(t,J=7.8Hz,1H),5.83(s,2H),4.19(q,J=7.0Hz,2H),1.24(t,J=6.8Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ158.78,157.44( 1 J CF =256.9Hz,4C),149.19,145.75,138.32,136.13,136.10,132.24,128.18, 128.14,128.11,125.88,125.85,125.74,125.18,125.07,124.43,123.00( 1 J CF =271.9Hz,29C),122.61,117.43(J CF =32.1,11.9Hz,5C),116.07,115.84,47.06,47.02,39.09,12.97.
[0152]
[0153] The preparation of the target compound 1-ethyl-3-hydroxy-6-(1-(4-(trifluoromethoxy)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-14) was carried out in the same manner as above. Yellow solid, yield 77%, mp: 234-236°C. ESI-MS: m / z 448.39 (M+H), 894.97 (2M+H).C 20 H 16 F3N5O4(447.12). 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.86(s,1H),8.51(d,J=2.1Hz,1H),8.23(dd,J=8.8,2.2Hz,1H),7.62(d,J =8.8Hz,1H),7.57–7.47(m,2H),7.41(d,J=8.4Hz,2H),5.71(s,2H),4.19(q,J=6.9Hz,2H),1.24(t,J=7.0Hz,3H).13 C NMR (125MHz, DMSO-d6) δ158.79,149.20,148.62,145.82,138.28,135.77,132.21,130.54,125.86,124.38,122.40,121.84,120.50( 1 J CF =256.5Hz,29C),116.07,115.92,115.83,52.73,39.09,12.97.
[0154]
[0155] The preparation of the target compound 1-ethyl-3-hydroxy-6-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-15) was carried out in the same manner as above. White solid, yield 77.8%, mp: 275-277°C. ESI-MS: m / z 407.5 (M-1) - .C 19 H 16 N6O5(408.37). 1 H NMR(400MHz, DMSO-d6)δ10.83(1H,s),8.89(1H,s),8.51(1H,d,J=2.04Hz),8.22-8.28( 3H,m),7.60-7.64(3H,m),5.86(2H,s),4.22(2H,q,J=6.84Hz),1.27(3H,t,J=6.96Hz). 13 C NMR(100MHz,DMSO-d6)δ158.79,149.19,147.74,145.85,143.69,138.29,132.19 ,129.60,125.73,124.43,124.38,122.72,116.05,115.87,52.70,47.15,12.99.
[0156]
[0157] The preparation of the target compound 1-ethyl-6-(1-(3-fluoro-4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-16) was carried out in the same manner as above. Yellow solid, yield 71%, mp: 250-252°C. ESI-MS: m / z 427.49 (M+H) + ,852.81(2M+H) + .C19 H 15 FN6O5(426.11). 1 H NMR (400MHz, DMSO-d6) δ10.90(s,1H),8.94(s,1H),8.57(d,J=2.2Hz,1H),8.35–8.21(m,2H),7.79– 7.63(m,2H),7.43(dd,J=8.6,1.8Hz,1H),5.89(s,2H),4.25(q,J=7.0Hz,2H),1.30(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ158.79,155.06( 1 J CF =262.3Hz,7C),149.20,145.87,145.27,145.19,138.33,136.94,136.87,132.21,127.39,127.36,125.71,125.08( 3 J CF =3.7Hz,5C),124.42,122.81,118.39( 2 J CF =31.6Hz,8C),116.06,115.89,52.30,39.11,13.00.
[0158]
[0159] The preparation of the target compound 1-ethyl-3-hydroxy-6-(1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-17) was carried out in the same manner as above. Yellow solid, yield 68%, mp: 236-238°C. ESI-MS: m / z 394.31 (M+H) + ,786.74(2M+H) + .C 20 H 19 N5O4(393.14). 1H NMR (400MHz, DMSO-d6) δ10.76(s,1H),8.77(s,1H),8.44(d,J=2.2Hz,1H),8.16(dd,J=8.8,2.2Hz,1H),7.55(d,J=8.9Hz,1H),7.25 (t,J=7.9Hz,1H),6.91(t,J=2.1Hz,1H),6.89–6.80(m,2H),5.55(s,2H),4.12(q,J=7.0Hz,2H),3.69(s,3H),1.17(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ159.95,158.81,149.20,145.72,138.24,137.75,132.20,130.46 ,125.91,124.32,122.30,120.57,116.05,115.84,114.32,114.02,55.60,53.56,13.00.
[0160]
[0161] The preparation of the target compound 6-(1-((6-chloropyridin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)-1-ethyl-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-18) was carried out in the same manner as above. White solid, yield 66%, mp: 210-212°C. ESI-MS: m / z 276.71 (2M+H) + .C 18 H 15 ClN6O3(398.09). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.85(s,1H),8.57–8.47(m,2H),8.23(dd,J=8.7,2.1Hz,1H),7.92–7.75(m,1H) ),7.63(d,J=8.8Hz,1H),7.58(d,J=8.2Hz,1H),5.73(d,J=8.2Hz,2H),4.19(q,J=7.0Hz,2H),1.24(t,J=7.0Hz,3H). 13C NMR(100MHz,DMSO-d6)δ158.32,150.76,150.69,150.23,149.20,145.85,142.13,140.32,140.05,138.31 ,132.18,131.85,131.51,128.78,125.76,125.03,124.39,122.43,116.06,115.88,50.31,50.26,13.00.
[0162]
[0163] The preparation of the target compound 1-cyclobutylmethyl-3-hydroxy-6-(1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-19) was carried out in the same manner as above. White solid, yield 54%, mp: 258-260°C. ESI-MS: m / z 472.28 (M+H) + .C 23 H 20 F3N5O3(471.15). 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.88(s,1H),8.49(d,J=2.1Hz,1H),8.20(dd,J=8.8,2.2Hz,1H),7.80(s,1H),7.78–7.70(m,1H),7.6 6(d,J=6.5Hz,2H),7.60(d,J=8.8Hz,1H),5.79(s,2H),4.23(d,J=7.1Hz,2H),2.76(p,J=7.4Hz,1H),2.02–1.92(m,2H),1.92–1.75(m,4H). 13 C NMR(125MHz,DMSO-d6)δ158.71,149.93,145.80,138.78,137.70,132.70,132.05,130.48,129.93( 2 J CF =31.8Hz,5C),125.84,125.49( 3 J CF =3.9Hz,4C),125.21( 3 J CF =3.9Hz, 6C),124.30,123.40,122.51,116.32,115.91,52.90,48.02,34.05,26.06,18.39.
[0164]
[0165] The preparation of the target compound 1-cyclobutylmethyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-20) was carried out in the same manner as above. White solid, yield 58%, mp: 250-252°C. ESI-MS: m / z 490.30 (M+H) + .C 23 H 19 F4N5O3(489.14). 1 H NMR(400MHz,DMSO-d6)δ10.81(d,J=1.5Hz,1H),8.86(s,1H),8.50(t,J=1.8H z,1H),8.21(dd,J=8.8,2.4Hz,1H),7.84(t,J=7.9Hz,1H),7.61(d,J=8.8Hz,1 H),7.55(d,J=11.6Hz,1H),7.36(d,J=8.1Hz,1H),5.81(s,2H),4.23(d,J=7.1 Hz,2H),2.73(d,J=7.5Hz,1H),1.98(p,J=7.0,6.5Hz,2H),1.92–1.76(m,4H). 13 CNMR (125MHz, DMSO-d6) δ159.34( 1 J CF =253.5Hz,1C),158.71,149.93,145.85,144.18,144.12,138.81,132.06,128.45,128.43(J CF =4.8Hz,5C),125.78,124.96,124.94,124.35,124.07,122.71,121.90,117.24,117.07,116.77(J CF =32.5,12.1Hz,6C),116.33,115.91,52.45,48.02,34.06,26.07,18.39.
[0166]
[0167] The preparation of the target compound 1-cyclobutylmethyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-21) was carried out in the same manner as above. White solid, yield 63%, mp: 142-144°C. ESI-MS: m / z 490.25 (M+H) + .C 23 H 19 F4N5O3(489.14). 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),8.84(s,1H),8.50(d,J=2.1Hz,1H),8.21(dd,J=8.8,2.2Hz,1H),7.79(d,J=10.0Hz,1H),7.66(d,J= 8.2Hz,1H),7.61(dd,J=8.3,6.1Hz,2H),5.83(s,2H),4.23(d,J=7.1Hz,2H),2.76(p,J=7.6Hz,1H),2.02–1.92(m,2H),1.91–1.75(m,4H). 13 C NMR(125MHz,DMSO-d6)δ160.35( 1 J CF =249.8Hz,4C),158.71,149.93,145.72,138.80,132.40,132.37,132.07,131.51(J CF =32.8,8.3Hz,6C),127.98,127.86,125.77,124.74,124.72,124.34,122.65,122.57,122.34,122.31,122.28,116.31,115.91,113.73(J CF =25.0,4.1Hz,5C),48.01,47.33,47.31,34.05,26.06,18.39.
[0168]
[0169] The preparation of the target compound 1-cyclobutylmethyl-3-hydroxy-6-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-22) was carried out in the same manner as above. Yellow solid, yield 70%, mp: 198-200°C. ESI-MS: m / z 449.26 (M+H) + ,896.67(2M+H) +.C 22 H 20 N6O5(448.15). 1 H NMR (400MHz, DMSO-d6) δ8.87(s,1H),8.52–8.48(m,1H),8.31–8.25(m,2H),8.21(dd,J=8.8,2.3Hz,1H),7.61(dd,J= 8.7,1.7Hz,3H),5.86(s,2H),4.24(d,J=7.2Hz,2H),2.75(q,J=7.4Hz,1H),1.97(d,J=5.8Hz,2H),1.91–1.78(m,4H). 13 C NMR(100MHz,DMSO-d6)δ158.73,149.94,147.76,145.83,143.72,138.80,132.05,129.6 1,125.76,124.45,124.29,122.75,116.38,115.90,52.69,48.00,34.02,26.06,18.41.
[0170]
[0171] The preparation of the target compound 1-allyl-3-hydroxy-6-(1-(3-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)quinoline-2,4(1H,3H)-dione (Ia-7-23) was carried out in the same manner as above. Yellow solid, yield 75%, mp: 208-210°C. ESI-MS: m / z 444.29 (M+H) + .C 21 H 16 F3N5O3(443.12). 1 H NMR (400MHz, DMSO-d6) δ10.90(s,1H),8.86(s,1H),8.51(s,1H),8.19(d,J=8.6Hz,1H),7.90–7.61(m,4H),7. 46(d,J=8.8Hz,1H),,5.96(ddt,J=15.6,9.7,4.6Hz,1H),5.79(s,2H),5.25–5.08(m,2H),4.91–4.59(m,2H). 13 C NMR (125MHz, DMSO-d6) δ158.86,149.48,145.81,138.56,137.70,132.71,132.40,132.01,130.49,129.93( 2 J CF=32.2Hz,5C),125.97,125.51,125.21,124.23,123.41,122.52,117.20,116.46,116.01,52.89,45.93.
[0172]
[0173] The preparation of the target compound 1-allyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline 3-(benzyloxy)-1-(cyclobutylmethyl)-6-iodoquinoline-2,4(1H,3H)-dione (Ia-7-24) was carried out in the same manner as above. Yellow solid, yield 72%, mp: 275-277°C. ESI-MS: m / z 462.24 (M+H) + .C 21 H 15 F4N5O3(461.11). 1 H NMR (400MHz, DMSO-d6) δ10.94(s,1H),8.86(s,1H),8.51(s,1H),8.20(d,J=8.5Hz,1H),7.83(t,J=7.8Hz,1H),7.55(d,J=11. 6Hz,1H),7.47(d,J=8.7Hz,1H),7.36(d,J=8.1Hz,1H),6.07–5.90(m,1H),5.81(s,2H),5.25–5.09(m,2H),4.93–4.68(m,2H). 13 CNMR(125MHz,DMSO-d6)δ158.87,149.50,145.87,144.20,144.14,132.42,132.00,130.12,128.47,128.43 ,125.91,124.98,124.95,124.27,122.74,121.91,117.25,117.19,117.08,116.47,116.02,52.44,45.93.
[0174]
[0175] The preparation of the target compound 1-allyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-25) was carried out in the same manner as above. White solid, yield 63%, mp: 202-204°C. ESI-MS: m / z 462.29 (M+H) + .C21 H 15 F4N5O3(461.11). 1 H NMR (400MHz, DMSO-d6) δ10.90(s,1H),8.83(s,1H),8.51(s,1H),8.20(d,J=8.1Hz,1H),7.78(d,J=9.9Hz,1H),7. 66(d,J=8.1Hz,2H),7.47(d,J=8.4Hz,1H),6.03–5.89(m,1H),5.83(s,2H),5.27–5.06(m,2H),4.92–4.66(m,2H). 13 C NMR(125MHz,DMSO-d6)δ160.36( 1 J CF =249.7Hz,4C),158.87,145.75,138.56,132.41,132.02,127.92(J CF =14.9Hz,2C),125.90,124.73,124.26,122.70,122.33,117.20,116.44,116.00,113.74(J CF =25.0Hz,5C),47.34,45.94.
[0176]
[0177] The preparation of the target compound 1-propyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ia-7-26) was carried out in the same manner as above. White solid, yield 58%, mp: 244-246°C. ESI-MS: m / z 464.29 (M+H) + .C 21 H 17 F4N5O3(463.13). 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.85(s,1H),8.51(d,J=2.0Hz,1H),8.22(d,J=7.6Hz,1H),7.79(d,J=10.0H z,1H),7.72–7.51(m,3H),5.83(s,2H),4.10(t,J=7.7Hz,2H),1.67(dt,J=15.6,8.0Hz,2H),0.96(t,J=7.4Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ160.35(1 J CF =249.8Hz,2C),158.76,149.50,145.74,138.60,132.39,132.36,132.16,131.52(J CF =33.1,8.2Hz,6C),127.93( 2 J CF =15.0Hz,3C),125.75,124.74,124.72,124.40,122.65,122.57,122.34,122.31,122.28,116.06,116.00,113.73(J CF =24.9,4.0Hz,1C),47.33,47.31,45.27,20.76,11.30.
[0178]
[0179] The preparation of the target compound 6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxy-1-isobutylquinoline-2,4(1H,3H)-dione (Ia-7-27) was carried out in the same manner as above. White solid, yield 59%, mp: 256-258°C. ESI-MS: m / z 478.31 (M+H) + .C 22 H 19 F4N5O3(477.14). 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.85(s,1H),8.51(d,J=2.1Hz,1H),8.21(dd,J=8.8,2.2Hz,1H),7.79(d,J=10.0Hz,1H ),7.66(d,J=8.2Hz,1H),7.61(d,J=8.3Hz,2H),5.83(s,2H),4.01(d,J=7.5Hz,2H),2.21–2.06(m,1H),0.94(d,J=6.6Hz,6H). 13 C NMR(125MHz,DMSO-d6)δ160.35( 1 J CF =249.8Hz,2C),158.71,149.91,145.72,138.84,132.38,132.35,131.45(J CF =32.9,8.3Hz,6C),127.93( 2 J CF=14.7Hz,3C),125.76,124.72,124.38,122.66,122.55,122.34,122.31,122.28,116.46,115.99,113.73(J CF =24.8,3.8Hz,1C),50.24,47.33,47.31,26.97,20.10.
[0180]
[0181] The preparation of the target compound 6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxy-1-(2-methylbutyl)quinoline-2,4(1H,3H)-dione (Ia-7-28) was carried out in the same manner as above. White solid, yield 66%, mp: 230-232°C. ESI-MS: m / z 492.37 (M+H) + .C 23 H 21 F4N5O3(491.16). 1 H NMR (400MHz, DMSO-d6) δ10.81 (s, 1H), 8.84 (s, 1H), 8.51 (d, J = 2.2Hz, 1H), 8. 22(dd,J=8.8,2.2Hz,1H),7.79(d,J=10.0Hz,1H),7.66(d,J=8.2Hz,1H),7.6 1(d,J=7.4Hz,1H),7.58(d,J=8.7Hz,1H),5.83(s,2H),4.15–3.93(m,2H),2. 02–1.82(m,1H),1.53–1.37(m,1H),1.28–1.12(m,1H),0.89(t,J=6.6Hz,6H). 13 C NMR(125MHz,DMSO-d6)δ160.35( 1 J CF =249.8Hz,2C),158.70,149.92,145.72,138.85,132.38,132.35,132.07,131.51(J CF =33.4,8.1Hz,6C),127.93( 2 J CF =14.3Hz,3C),125.77,124.73,124.39,122.66,122.56,122.34,122.31,122.28,116.41,116.01,113.73(J CF=24.9,4.1Hz,1C),49.13,47.34,47.31,33.22,26.69,16.73,11.58.
[0182]
[0183] The preparation of the target compound 6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)-3-hydroxy-1-isopentylquinoline-2,4(1H,3H)-dione (Ia-7-29) was carried out in the same manner as above. White solid, yield 63%, mp: 210-212°C. ESI-MS: m / z 492.38 (M+H) + .C 23 H 21 F4N5O3(491.16). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.84(d,J=1.9Hz,1H),8.51(d,J=2.2Hz,1H),8.24(dt,J=8.7,2.2Hz,1H),7.79(d,J=9.9Hz,1H),7.71–7.58( m,2H),7.54(dd,J=8.9,1.9Hz,1H),5.83(s,2H),4.15(t,J=7.8Hz,2H),1 .78–1.63(m,1H),1.52(q,J=7.9,7.0Hz,2H),0.97(dd,J=6.6,2.0Hz,6H). 13 C NMR(125MHz,DMSO-d6)δ160.36( 1 J CF =249.8Hz,2C),158.74,149.36,145.73,138.42,132.41,132.38,132.24,131.52(J CF =33.1,8.2Hz,6C),127.91( 2 J CF =14.8Hz,3C),125.75,124.74,124.72,124.44,122.64,122.34,122.31,122.28,116.07,115.87,113.73(J CF =24.8,3.9Hz,1C),47.33,47.31,42.38,36.15,25.99,22.85.
[0184] Example 5: Preparation of target compounds Ib-5-1 to Ib-5-9
[0185]
[0186] The intermediate compound Ia-2b (1.0 equiv), the amino group of which is protected by Boc and replaced by a nitrogen-containing heterocycle (1.2 equiv) with a boronic acid, and tetrakis(triphenylphosphine)palladium (0.1 equiv) are added to a 15 mL 1,4-dioxane solution, and then an aqueous solution of sodium carbonate (2.0 equiv) is added, and the mixture is subjected to microwave reaction at 120° C.-130° C. for 20-30 min; the reaction solution is then filtered through diatomaceous earth, and the filtrate is evaporated to dryness to obtain the crude intermediate compounds Ib-2-1-Ib-2-9;
[0187] Then, for different target products, the present invention adopts different synthesis methods. The target compounds Ib-5-1 to Ib-5-5 are prepared by method one, and the target compounds Ib-5-6 to Ib-5-9 are prepared by method two.
[0188] Method 1: Dissolve the intermediate compound Ib-2-1-Ib-2-5 (1.0 equiv) in methanol solution, add potassium carbonate (3.0 equiv), and reflux for 0.5-2 h; evaporate the solvent under reduced pressure, add aqueous solution to the concentrate, stir at room temperature for 0.5 h, filter, and dry the filter cake to obtain the crude intermediate compound Ib-3-1-Ib-3-5; dissolve the obtained intermediate compound Ib-3-1-Ib-3-5 (1.0 equiv) in N,N-dimethylformamide solution, add Add sodium hydrogen sulfide (1.5 equiv), and then stir at room temperature for 2-12 h; slowly add ice water dropwise to the reaction solution to generate a large amount of precipitate, filter, wash the filter cake with water, and dry the filter cake to obtain the crude intermediate compound Ib-4-1-Ib-4-5; add 3 mL of glacial acetic acid and 2 mL of hydrobromic acid to the intermediate compound Ib-4-1-Ib-4-5 (0.4 mmol), heat to reflux for 0.5-2 h; cool to room temperature, and concentrate under reduced pressure; then recrystallize from methanol to obtain the target product Ib-5-1-Ib-5-5.
[0189] Method 2: Add 2M hydrochloric acid ethyl acetate solution to the intermediate compound Ib-2-6-Ib-2-9 (1.0 equiv), stir at room temperature for 0.5-3 h; after the reaction is complete, evaporate the solvent under reduced pressure, add saturated sodium bicarbonate aqueous solution to the concentrate, stir at room temperature for 0.5 h, filter, wash the filter cake with water, and dry the filter cake to obtain the crude intermediate compound Ib-3-6-Ib-3-9; dissolve the obtained intermediate compound Ib-3-6-Ib-3-9 (1.0 equiv) in N,N-dimethylformamide solution, add carbonate Potassium (2.0 equiv) and potassium iodide (1.0 equiv), stirring at room temperature for 8-12 h; slowly add water dropwise to the reaction solution to generate a large amount of precipitate, filter, wash the filter cake with water, and dry the filter cake to obtain the crude intermediate compound Ib-4-6-Ib-4-9; add 3 mL of glacial acetic acid and 2 mL of hydrobromic acid to the intermediate compound Ib-4-6-Ib-4-9 (0.4 mmol), heat to reflux for 0.5-2 h; cool to room temperature, concentrate under reduced pressure; then recrystallize from methanol to obtain the target product Ib-5-6-Ib-5-9.
[0190]
[0191] The preparation of the target compound 1-ethyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-1) was carried out in the same manner as above. White solid, yield 48%, mp: 218-220°C. ESI-MS: m / z 449.29 (M+H) + ,896.87(2M+H) + .C 21 H 16 F4N4O3(448.12). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.44(d,J=2.1Hz,1H),8.17(dd,J=8.8,2.2Hz,1H),8.02(d,J=2.3Hz,1H),7.80(t,J=7.9Hz,1H),7.57(d ,J=8.8Hz,1H),7.40(d,J=11.7Hz,1H),7.25(d,J=8.1Hz,1H),6.92(d,J=2.3Hz,1H),5.55(s,2H),4.18(q,J=7.0Hz,2H),1.24(t,J=7.0Hz,3H). 13 CNMR (125MHz, DMSO-d6) δ159.32( 1 J CF=253.1Hz,25C),158.89,149.97,149.19,146.22( 3 J CF =7.7Hz,19C),138.03,133.45,132.30,128.41,128.25,128.21,128.18,126.30,124.27,124.24,124 .13,121.97,116.41,116.29,116.24,116.13,116.03,115.91,115.52,103.72,54.32,39.03,12.96.
[0192]
[0193] The preparation of the target compound 1-ethyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-2) was carried out in the same manner as above. White solid, yield 52%, mp: 194-196°C. ESI-MS: m / z 449.33 (M+H) + ,896.74(2M+H) + .C 21 H 16 F4N4O3(448.12). 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.44–8.36(m,1H),8.15(ddd,J=8.9,6.8,2.2Hz,1H),7.99(t,J=2.7Hz,1H),7.76(d,J=10.2Hz ,1H),7.62(d,J=7.2Hz,1H),7.54(dd,J=19.2,8.9Hz,1H),7.38(t,J=7.7Hz,1H),5.58(s,2H),4.23–4.04(m,2H),1.27–1.17(m,3H). 13 C NMR(125MHz,DMSO-d6)δ161.62( 1 J CF =248.7Hz,20C),158.88,149.91,149.19,138.03,133.48,133.43,132.51,132.30,131.57,131.54,131.51,130.82(J CF=33.3,8.9Hz,1C),129.84,129.72,128.40,128.01,124.81,124.11,122.64,122.16,122.12,116.52,115.89,115.53,115.45,113.46( 2 J CF =24.3Hz,25C),103.63,103.53,49.08,39.03,12.96,12.94.
[0194]
[0195] The preparation of the target compound 1-ethyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-3) was carried out in the same manner as above. White solid, yield 46%, mp: 120-122°C. ESI-MS: m / z 449.29 (M+H) + .C 21 H 16 F4N4O3(448.12). 1 H NMR (400MHz, DMSO-d6) δ10.75(s,1H),8.51(d,J=0.9Hz,1H),8.22(d,J=2.3Hz,1H),8.08(d,J=0.7Hz,1H),8.00(dd,J=8.8,2.3Hz,1H),7.80( t,J=7.9Hz,1H),7.54(d,J=8.8Hz,1H),7.(d,J=11.7Hz,1H),7.27(d,J=8.1Hz,1H),5.49(s,2H),4.18(q,J=7.0Hz,2H),1.23(t,J=7.0Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ158.93,149.19,145.91( 3 J CF =8.6Hz,10C),137.61,136.96,132.50,128.65,128.19,127.64,124.48,124.45,123.66,121.31, 116.61,116.40,115.99,115.79,54.35,40.34,40.13,39.93,39.72,39.51,39.30,39.09,12.96.
[0196]
[0197] The preparation of the target compound 1-ethyl-6-(1-(2-fluoro-4-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-4) was carried out in the same manner as above. White solid, yield 55%, mp: 128-130°C. ESI-MS: m / z 449.25 (M+H) + .C 21 H 16 F4N4O3(448.12). 1 H NMR (400MHz, DMSO-d6) δ10.75(s,1H),8.50(s,1H),8.21(d,J=2.3Hz,1H),8.06(d,J=0.7Hz,1H),7.99(dd,J=8.8,2.3Hz,1H),7.74(dd,J=10. 0,1.8Hz,1H),7.61(d,J=7.7Hz,1H),7.54(d,J=8.8Hz,1H),7.44(t,J=7.7Hz,1H),5.52(s,2H),4.18(q,J=7.0Hz,2H),1.23(t,J=7.0Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ158.85,149.17,137.56,136.98,132.43,131.87,12 8.65,127.69,123.71,122.13,121.23,116.08,115.73,49.04,38.95,13.00.
[0198]
[0199] The preparation of the target compound 1-ethyl-6-(1-(3-fluoro-4-(trifluoromethyl)benzyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-5) was carried out in the same manner as above. White solid, yield 43%, mp: 234-236°C. ESI-MS: m / z 447.46 (M+H) + .C 23 H 20 F4N4O3(476.15). 1H NMR (400MHz, DMSO-d6) δ7.91(d,J=2.2Hz,1H),7.78–7.67(m,2H),7.59(t,J=9.0Hz,2H),7.24(t,J =7.6Hz,1H),5.43(s,2H),4.19(q,J=7.0Hz,2H),2.27(s,3H),2.16(s,3H),1.25(t,J=7.0Hz,3H). 13 CNMR (125MHz, DMSO-d6) δ159.82( 1 J CF =247.5Hz, 4C),149.26,145.39,137.46,137.15,136.30,131.22,131.18,130.76,130.69,130.50,129.78,129.66,128.51,127.92,123.76( 1 J CF =269.6Hz,31C),122.21,122.18,122.15,117.52,115.80,115.48,113.39(J CF =24.9,3.8Hz,1C),46.11,46.08,39.01,13.00,12.82,10.23.
[0200]
[0201] The preparation of the target compound 1-ethyl-6-(4-(3-fluoro-4-(trifluoromethyl)benzyl)piperazin-1-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-6) was carried out in the same manner as above. White solid, yield 46%, mp: 250-252°C. ESI-MS: m / z 467.17 (M+H) + .C 22 H 22 F4N4O3(466.16). 1 H NMR (400MHz, DMSO-d6) δ10.72(s,1H),7.98(t,J=7.8Hz,1H),7.76(d,J=11.4Hz,1H),7.62(d,J=8.1Hz,1H),7.58–7.42(m,3H),4.5 6(s,2H),4.14(q,J=7.0Hz,2H),3.99–3.82(m,2H),3.60–3.45(m,2H),3.30–3.19(m,2H),3.14–2.95(m,2H),1.20(t,J=7.0Hz,3H). 13C NMR(125MHz,DMSO-d6)δ160.07,159.06( 1 J CF =255.1Hz,21C),149.00,145.50,137.67,132.45,128.69,128.46,125.04,122.90( 1 J CF =272.2Hz,30C),120.63,120.46,116.33,116.10,113.00,57.65,51.10,46.09,38.84,13.04.
[0202]
[0203] The preparation of the target compound 1-ethyl-6-(4-(2-fluoro-4-(trifluoromethyl)benzyl)piperazin-1-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-7) was carried out in the same manner as above. White solid, yield 42%, mp: 218-220°C. ESI-MS: m / z 467.42 (M+H) + ,932.92(2M+H) + .C 22 H 22 F4N4O3(466.16). 1 H NMR (400MHz, DMSO-d6) δ10.04(s,1H),8.01–7.87(m,2H),7.80(d,J=8.1Hz,1H),7.56–7.40(m,3H),4.60(s,2H),4. 21–4.03(m,2H),4.01–3.79(m,2H),3.70–3.59(m,2H),3.35–3.27(m,2H),3.16–2.93(m,2H),1.20(t,J=6.9Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ161.58( 1 J CF =251.2Hz,20C),158.83,149.00,145.52,136.06,136.03,132.95(J CF =33.6,8.6Hz,4C),132.43,125.04,123.55( 1 J CF =273.4Hz,30C),122.23,122.20,121.85,121.73,116.34,116.08,114.00(J CF=24.9,3.8Hz,21C),112.93,51.77,51.14,46.08,38.84,13.04.
[0204]
[0205] The preparation of the target compound 1-ethyl-6-(4-(2-fluoro-4-(trifluoromethyl)benzyl)-2-oxopiperazin-1-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-8) was carried out in the same manner as above. White solid, yield 48%, mp: 178-180°C. ESI-MS: m / z 481.28 (M+H) + ,960.98(2M+H) + .C 22 H 20 F4N4O4(480.14). 1 H NMR (400MHz, DMSO-d6) δ8.01(d,J=2.6Hz,1H),7.94(t,J=7.6Hz,1H),7.88(d,J=9.8Hz,1H),7.77(d,J=8.0Hz,1H),7.72(dd,J=9.0,2.6Hz ,1H),7.61(d,J=9.1Hz,1H),4.49(s,2H),4.17(q,J=7.0Hz,2H),3.83–3.73(m,2H),3.60–3.52(m,2H),3.17(s,2H),1.22(t,J=7.0Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ161.48( 1 J CF =251.1Hz,20C),158.44,149.20,137.52,136.14,135.27,133.33,125.32,123.59( 1 J CF =273.7Hz,31C),122.29,116.14,116.04,114.04(J CF =25.9,4.0Hz,21C),53.81,51.90,48.25,46.88,39.21,12.91.
[0206]
[0207] The preparation of the target compound 1-ethyl-6-(4-(3-fluoro-4-(trifluoromethyl)benzyl)-2-oxopiperazin-1-yl)-3-hydroxyquinoline-2,4(1H,3H)-dione (Ib-5-9) was carried out in the same manner as above. White solid, yield 42%, mp: 192-194°C. ESI-MS: m / z 481.26 (M+H) + ,960.95(2M+H) + .C 22 H 20 F4N4O4(480.14). 1 H NMR (400MHz, DMSO-d6) δ10.62(s,1H),8.03(d,J=2.6Hz,1H),7.94(t,J=7.8Hz,1H),7.80–7.70(m,2H),7.62(dd,J=8.7,4 .3Hz,2H),4.41(s,2H),4.17(q,J=7.0Hz,2H),3.94–3.87(m,2H),3.85–3.75(m,2H),3.40(s,2H),1.23(t,J=7.0Hz,3H). 13 C NMR(125MHz,DMSO-d6)δ162.35,159.18( 1 J CF =254.5Hz,21C),158.45,149.20,137.53,136.13,133.36,128.47,128.43,128.13,125.37,122.95( 1 J CF =254.5Hz,31C),120.10,119.93,119.70,116.13,116.04,57.72,53.53,48.37,46.68,39.21,12.92.
[0208] Example 6. In vitro anti-monkeypox virus activity test (HEL cells) experiment of the target compound
[0209] Test Principle
[0210] Viruses can replicate and proliferate only in susceptible living animals, chicken embryos or cells. Therefore, animals, chicken embryos or cells can be used for virus culture and antiviral testing of drugs. The antiviral test effect of drugs can be judged by observing changes in the pH of cell culture fluid, the cytopathic effect (CPE) of the virus, the plaque assay (Plaque assay, PFU), changes in the mRNA level of the viral genome, changes in chicken embryo allantoic fluid or animal serum and other corresponding indicators.
[0211] Virus plaques, also known as empty plaques, are formed after the virus infects cells. Due to the limitation of solid media, the released viruses can only spread from the initially infected cells to the periphery. After several proliferation cycles, a localized diseased cell area is formed. Combined with active dye staining, live cells are stained, and cells damaged by virus infection are not stained, forming plaques visible to the naked eye. Theoretically, one virus particle can form one plaque. Conversely, each plaque produced means that there is a live virus particle in the experimental environment. Virus empty plaque test is one of the most widely used methods for detecting virus titers.
[0212] Plaque Forming Units (PFU) refers to the number of infectious virus particles that can form a visible plaque in cell culture. Each plaque represents one or a group of virus particles that can infect host cells and cause cell lysis. PFU is a standard unit for quantifying virus concentration. This test uses a viral infection dose of 100 PFU.
[0213] Test method:
[0214] Virus plaque assay (PlaqueAssay)
[0215] HEL cells were digested, centrifuged, counted, and plated in a 96-well plate. After culturing for 24 hours at 37°C and 5% CO2, 100 PFU of monkeypox virus (2022MPXV isolate) was added to infect the cells. After 1 hour, the residual virus was removed, and a culture medium containing different concentrations of the compound was added. The culture was continued for 1 hour, and the cells were covered with 1.6% carboxymethyl cellulose diluted in the culture medium. After culturing for 1-3 days, when the virus plaques in the virus-infected cells in the control group were observed to be completely formed, the cells were fixed with 3.7% formaldehyde and the fixative was removed. The monolayer cells were then stained with 0.1% crystal violet and 1.5% methanol. The staining solution was removed, and the number of virus plaques in each well was observed and counted under a microscope. The concentration of the compound that reduced the formation of virus plaques by 50% was obtained as the antiviral activity of the target compound (EC 50 ).
[0216] Cytotoxicity testing is based on the inhibitory effect of the test compound on cell growth. First, 5 × 10 3 HEL cells were incubated at 37°C and 5% CO2 for 24 hours; then medium containing different concentrations of the test compound was added and incubated at 37°C and 5% CO2 for 3 days; then the number of cells in each well was determined using a Coulter counter. 50The MCC is the minimum concentration of a compound required to produce changes in normal cell morphology visible under a microscope.
[0217] Table 1. Anti-monkeypox virus activity and toxicity of some heterocyclic azadione compounds (HEL cells)
[0218]
[0219] a EC 50 : The concentration of the compound that inhibits 50% of the virus-induced mutagenic effect or protects 50% of the virus-infected cells from cytopathic effects; A represents the EC of the compound 50 <100nM, B represents compound EC 50 The value is 100-1000nM, and C represents the EC of the compound. 50 >1000nM.
[0220] b MCC: The minimum concentration of a compound required to cause microscopic changes in normal cell morphology.
[0221] c CC 50 : The concentration of compound required to reduce cell growth by 50%.
[0222] d ND: Not determined.
[0223] Experimental conclusion analysis: Most of the newly synthesized heterocyclic azepine dione derivatives showed significant anti-monkeypox virus activity. Among them, the anti-monkeypox virus activities of compounds Ia-7-3, Ia-7-10, Ia-7-11, Ia-7-20, Ia-7-21, Ia-7-24, Ia-7-25, Ia-7-26, Ia-7-27, Ia-7-28 and Ia-7-29 were all less than 100nM. In addition, most of the newly synthesized heterocyclic azepine dione derivatives did not show obvious cytotoxicity.
Claims
1. A heterocyclic azadione derivative and its tautomer, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt, ester or prodrug thereof, having a structure shown in the following general formula I: in, n = 0, 1, 2 or 3; X is: C or N; Y is: -OH, -R p , -NR p R q , -NO2, -COOR p ; One and only one of X and Y contains N; V 1 N or C (U 1 ); V 2 N or C (U 2 ); V 3 N or C (U 3 ); And V 1 , V 2 and V 3 There is only one N; Among them, U 1 , U 2 and U 3 Each is independently selected from: H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, benzyl, trifluoromethyl, -C(=O)(C1-C6 alkyl), -C(=O)NR p R q 、-NR p R q 、-NR p C(=O)R s 、-NR p C(=O)OR s 、-NR p C(=O)NR q R r 、-OR s 、-OC(=O)R s 、-OC(=O)OR s ; R 1 is: H, -OH, C1-C6 alkyl, OC1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, -C(=O)(C1-C6 alkyl), -C(=O)NR p R q , trifluoromethyl, substituted phenyl, substituted benzyl, substituted naphthalene ring, various substituted six-membered heterocycles, various substituted five-membered heterocycles or various substituted four-membered heterocycles; the substituents are one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl; R 2 is: C1-C6 alkyl, OC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, substituted phenyl, substituted naphthalene ring, various substituted six-membered heterocycles, various substituted five-membered heterocycles, various substituted six-membered and five-membered heterocycles, various substituted six-membered and six-membered heterocycles, various substituted five-membered and five-membered heterocycles, various substituted benzo five-membered heterocycles or various substituted benzo six-membered heterocycles; the substituent is one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl; W is: C5-C6 cycloalkyl, C4-C5 azacycloalkyl, various substituted six-membered heterocycles, various substituted five-membered heterocycles, various substituted six-membered and five-membered heterocycles, various substituted six-membered and six-membered heterocycles, various substituted five-membered and five-membered heterocycles; the substituents are one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl; R p , R q , R s and R r is independently selected at each occurrence from hydrogen, C1-C4 alkyl and C3-C6 cycloalkyl; in: R p , R q , R s and R r The C1-C4 alkyl in any one of the groups is optionally substituted with 1 to 3 groups selected from halogen, cyano and hydroxy.
2. A heterocyclic azadione derivative according to claim 1, characterized in that: n = 0 or 1; X is N; Y is -OH; R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl, V 1 、V 2 and V 3 All are C; W is: 1,2,3-triazole, pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine; R 2 is a substituted six-membered aromatic ring having the general formula a; Among them, V 4 C or N; R 3 is halogen, -OH, -OCH3, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R 3 It may be monosubstituted, disubstituted or trisubstituted.
3. A heterocyclic azadione derivative according to claim 2, characterized in that It is a compound represented by formula Ia: in, n = 0 or 1; R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl, V 1 、V 2 and V 3 All are C; R 2 is a substituted six-membered aromatic ring having the general formula a; Among them, V 4 C or N; R 3 is halogen, -OH, -OMe, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R 3 It may be monosubstituted, disubstituted or trisubstituted.
4. A heterocyclic azadione derivative as claimed in claim 2, characterized in that It is a compound shown in formula Ib: in, R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, allyl, V 1 、V 2 and V 3 All are C; is: pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine; R 2 is a substituted six-membered aromatic ring having the general formula a; Among them, V 4 C or N; R 3 is halogen, -OH, -OCH3, -CN, -NO2, -NH2, -CF3, -CONH2, -COOCH3, -SO2NH2, -SO2CH3, -NHCH3, -NHCOCH3, -NHSO2CH3 or -NHSO2CF3, R 3 It may be monosubstituted, disubstituted or trisubstituted.
5. A heterocyclic azadione derivative according to any one of claims 1 to 4, characterized in that The pharmaceutically acceptable salt of the compound is sodium salt, potassium salt, hydrochloride, sulfate, tartrate, phosphate, salicylate, maleate, oxalate, succinate or citrate.
6. A heterocyclic azadione derivative as claimed in claim 3 or 4, characterized in that is one of the following compounds:
7. The method for preparing a heterocyclic azadione derivative according to claim 3, characterized in that: Here are the steps: Compound A is used as a starting material, and is first reacted with N,N'-carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound B; the intermediate compound B undergoes an alkylation reaction at the N-1 position under the action of potassium carbonate to form an intermediate compound C; the intermediate compound C undergoes a Sonogaoka coupling reaction with trimethylsilylacetylene under the conditions of cuprous iodide, bis(triphenylphosphine)palladium dichloride as a catalyst and triethylamine as a base to obtain a key intermediate compound D; then the intermediate compound D is deprotected from silicon under the action of potassium carbonate to obtain an intermediate E; the intermediate compound E undergoes an azide-alkynyl cycloaddition reaction under the catalysis of Cu(I) generated by the reaction of sodium ascorbate and copper sulfate pentahydrate to form an intermediate compound F; the intermediate compound F is refluxed in a hydrobromic acid and glacial acetic acid system to deprotect the benzyl group to form a target product Ia; The synthetic route is as follows: Reagents and conditions: (i) (a) N, N'-carbonyldiimidazole, tetrahydrofuran; (b) o-benzylhydroxylamine, reflux; (c) sodium hydroxide, ethanol, reflux; (d) acetic acid, room temperature; (ii) iodinated alkanes, iodinated cycloalkanes, iodinated olefins, iodinated alkynes, iodinated heteroatom-containing alkanes or iodinated heteroatom-containing cycloalkanes, K2CO3, N, N-dimethylformamide, room temperature or bromoalkanes, bromocycloalkanes, bromoolefins, bromoalkynes, Brominated heteroatom-containing alkane or brominated heteroatom-containing cycloalkane, K2CO3, KI, N,N-dimethylformamide, 20-65°C; (iii) cuprous iodide, bis(triphenylphosphine)palladium dichloride, triethylamine, trimethylsilyl acetylene, tetrahydrofuran, room temperature; (iv) potassium carbonate, methanol, room temperature; (v) sodium ascorbate, copper sulfate pentahydrate, water, tetrahydrofuran, azide, 20-65°C; (vi) hydrobromic acid, acetic acid, reflux; R 1 , R 2 、V 1 , V 2 , V 3 and n is the same as that shown in the general formula Ia of claim 3; The azide is a substituted benzene ring azide, a substituted naphthalene ring azide, various substituted six-membered heterocyclic azides, various substituted five-membered heterocyclic azides, various substituted six-membered and five-membered heterocyclic azides, various substituted six-membered and six-membered heterocyclic azides, and various substituted five-membered and five-membered heterocyclic azides; the substituent is one or more, independently selected from halogen, hydroxyl, amino, nitro, -SO2CH3, -CONH2, -CN, -CF3, -NHCH3, -COOH, -CH2OH, -CO2CH3, -OCH3, -NHCOCH3, C1-C6 alkyl or C3-C6 cycloalkyl.
8. The method for preparing a heterocyclic azadione derivative according to claim 4, characterized in that: Here are the steps: The intermediate compound C obtained in the general scheme A is used as a starting material, and various boronic acid-substituted nitrogen-containing heterocycles whose amino groups are protected by Boc are subjected to Suzuki reaction under the conditions of tetrakis(triphenylphosphine)palladium as a catalyst and sodium carbonate as a base to obtain the intermediate compound G; the intermediate compound G is deprotected from the amino group under acidic or alkaline conditions to obtain the intermediate compound H; The intermediate compound H undergoes nucleophilic substitution with the halogen-substituted benzyl group under alkaline conditions to obtain the intermediate compound J; the intermediate compound J is refluxed in a hydrobromic acid and glacial acetic acid system to remove the benzyl protection to generate the target product Ib; Reagents and conditions: (i) various amino groups substituted with boric acid protected by Boc, sodium carbonate, tetrakis(triphenylphosphine)palladium, 1,4-dioxane / water, microwave at 120℃-130℃; (ii) hydrochloric acid in ethyl acetate, room temperature or potassium carbonate, methanol, reflux (iii) potassium carbonate or sodium hydrogen sulfide, N,N-dimethylformamide, room temperature; (iv) hydrobromic acid, acetic acid, reflux; R 1 , R 2 、V 1 , V 2 and V 3 As shown in the general formula Ib of claim 4; The nitrogen-containing heterocyclic ring whose various amino groups are substituted by boric acid protected by Boc is pyrrole, pyrazole, imidazole, piperazine, piperazinone or tetrahydropyridine; The halogen-substituted benzyl aromatic ring is the same as the substituted six-membered aromatic ring having the general formula a as shown in the general formula Ib of claim 4.
9. Use of the compound according to any one of claims 1 to 6 in the preparation of anti-monkeypox virus drugs.
10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 and one or more pharmaceutically acceptable carriers or excipients.
Citation Information
Patent Citations
N-hydroxyl heterocycle pyrimindine diketone derivative and preparation method and application thereof
CN105669653A
Antiviral pyridopyrazinedione compounds
CN112996789A
Pyridine-2 (1H)-ketone HIV-1 (human immunodeficiency virus-1) non-nucleoside reverse transcriptase inhibitor as well as preparation method and application thereof
CN117924242A
Cited By
N-hydroxyl thienopyrimidinedione derivative as well as preparation method and application thereof
CN119080799A
An N-hydroxythienopyrimidinedione derivative, and a preparation method and application thereof
CN119080799B
